Delving into the Latest Updates on AviGenics, Inc. with Synapse

概览

关联

1

项与 AviGenics, Inc. 相关的临床试验

NCT00497809

/ Completed临床2期

An Open-Label, Dose Finding, Prospective, Multi Center, Randomized, Parallel Group Study to Assess the Efficacy and Safety of Three Different Dose Levels of AVI 014 (G-CSF) Compared With a Standard Dose of Neupogen® in Breast Cancer Patients at High (>20%) Risk for Chemotherapy Induced Severe Neutropenia

The overall purpose of this study is to assess the dose response, efficacy, and safety of three different dose levels of AVI 014 (granulocyte colony-stimulating factor [G-CSF]) in breast cancer patients at high (>20%) risk for chemotherapy-induced severe neutropenia.

开始日期2007-08-01

申办/合作机构

AviGenics, Inc.

100 项与 AviGenics, Inc. 相关的临床结果

登录后查看更多信息

0 项与 AviGenics, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 AviGenics, Inc. 相关的药物交易

登录后查看更多信息

100 项与 AviGenics, Inc. 相关的转化医学

登录后查看更多信息